Literature DB >> 34117482

Amyloid-β: a potential link between epilepsy and cognitive decline.

Michele Romoli1,2,3,4, Arjune Sen2, Lucilla Parnetti1, Paolo Calabresi5,6, Cinzia Costa7.   

Abstract

People with epilepsy - in particular, late-onset epilepsy of unknown aetiology - have an elevated risk of dementia, and seizures have been detected in the early stages of Alzheimer disease (AD), supporting the concept of an epileptic AD prodrome. However, the relationship between epilepsy and cognitive decline remains controversial, with substantial uncertainties about whether epilepsy drives cognitive decline or vice versa, and whether shared pathways underlie both conditions. Here, we review evidence that amyloid-β (Aβ) forms part of a shared pathway between epilepsy and cognitive decline, particularly in the context of AD. People with epilepsy show an increased burden of Aβ pathology in the brain, and Aβ-mediated epileptogenic alterations have been demonstrated in experimental studies, with evidence suggesting that Aβ pathology might already be pro-epileptogenic at the soluble stage, long before plaque deposition. We discuss the hypothesis that Aβ mediates - or is at least a major determinant of - a continuum spanning epilepsy and cognitive decline. Serial cognitive testing and assessment of Aβ levels might be worthwhile to stratify the risk of developing dementia in people with late-onset epilepsy. If seizures are a clinical harbinger of dementia, people with late-onset epilepsy could be an ideal group in which to implement preventive or therapeutic strategies to slow cognitive decline.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34117482     DOI: 10.1038/s41582-021-00505-9

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  191 in total

Review 1.  Alzheimer's disease and other dementias: update on research.

Authors:  Lon Schneider
Journal:  Lancet Neurol       Date:  2017-01       Impact factor: 44.182

2.  Response to the growing dementia burden must be faster.

Authors: 
Journal:  Lancet Neurol       Date:  2018-07-17       Impact factor: 44.182

3.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

4.  Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link?

Authors:  Cinzia Costa; Lucilla Parnetti; Marcello D'Amelio; Alessandro Tozzi; Michela Tantucci; Andrea Romigi; Sabrina Siliquini; Virve Cavallucci; Massimiliano Di Filippo; Petra Mazzocchetti; Claudio Liguori; Annalisa Nobili; Paolo Eusebi; Nicola B Mercuri; Paolo Calabresi
Journal:  Neurobiol Aging       Date:  2016-09-03       Impact factor: 4.673

5.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

6.  Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy.

Authors:  Rimante Minkeviciene; Sylvain Rheims; Marton B Dobszay; Misha Zilberter; Jarmo Hartikainen; Lívia Fülöp; Botond Penke; Yuri Zilberter; Tibor Harkany; Asla Pitkänen; Heikki Tanila
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

Review 7.  Alzheimer's disease.

Authors:  Colin L Masters; Randall Bateman; Kaj Blennow; Christopher C Rowe; Reisa A Sperling; Jeffrey L Cummings
Journal:  Nat Rev Dis Primers       Date:  2015-10-15       Impact factor: 52.329

Review 8.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

Authors:  George S Bloom
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 9.  Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.

Authors:  Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz
Journal:  Nat Rev Neurol       Date:  2017-12-15       Impact factor: 42.937

10.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.

Authors:  Clifford R Jack; Heather J Wiste; Hugo Botha; Stephen D Weigand; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; David T Jones; Tanis J Ferman; Bradley F Boeve; Kejal Kantarci; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Julie A Fields; Mary M Machulda; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Ronald C Petersen
Journal:  Brain       Date:  2019-10-01       Impact factor: 13.501

View more
  10 in total

1.  Early death in a mouse model of Alzheimer's disease exacerbated by microglial loss of TAM receptor signaling.

Authors:  Youtong Huang; Greg Lemke
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-03       Impact factor: 12.779

Review 2.  Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications.

Authors:  Miren Altuna; Gonzalo Olmedo-Saura; María Carmona-Iragui; Juan Fortea
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

3.  Key gene network related to primary ciliary dyskinesia in hippocampus of patients with Alzheimer's disease revealed by weighted gene co-expression network analysis.

Authors:  Pengcheng Xia; Jing Chen; Xiaohui Bai; Ming Li; Le Wang; Zhiming Lu
Journal:  BMC Neurol       Date:  2022-05-30       Impact factor: 2.903

4.  Association of cognitive enhancers and incident seizure risk in dementia: a population-based study.

Authors:  Junghee Ha; Nak-Hoon Son; Young Ho Park; Eun Lee; Eosu Kim; Woo Jung Kim
Journal:  BMC Geriatr       Date:  2022-06-03       Impact factor: 4.070

5.  The Contribution of HCN Channelopathies in Different Epileptic Syndromes, Mechanisms, Modulators, and Potential Treatment Targets: A Systematic Review.

Authors:  Miriam Kessi; Jing Peng; Haolin Duan; Hailan He; Baiyu Chen; Juan Xiong; Ying Wang; Lifen Yang; Guoli Wang; Karlmax Kiprotich; Olumuyiwa A Bamgbade; Fang He; Fei Yin
Journal:  Front Mol Neurosci       Date:  2022-05-19       Impact factor: 6.261

Review 6.  Beyond Seizure Control: Treating Comorbidities in Epilepsy via Targeting of the P2X7 Receptor.

Authors:  Beatriz Gil; Jonathon Smith; Yong Tang; Peter Illes; Tobias Engel
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

Review 7.  Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy.

Authors:  Jacopo C DiFrancesco; Angelo Labate; Michele Romoli; Elena Chipi; Nicola Salvadori; Carlo Andrea Galimberti; Daniela Perani; Carlo Ferrarese; Cinzia Costa
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

8.  The landscape in the gut microbiome of long-lived families reveals new insights on longevity and aging - relevant neural and immune function.

Authors:  Jingjing Wang; Jinlong Qie; Danrong Zhu; Xuemei Zhang; Qingqing Zhang; Yuyu Xu; Yipeng Wang; Kai Mi; Yang Pei; Yang Liu; Guozhong Ji; Xingyin Liu
Journal:  Gut Microbes       Date:  2022 Jan-Dec

9.  Late-onset seizures and epilepsy: Electroclinical features suggestive of autoimmune etiology.

Authors:  Alessandra Morano; Emanuele Cerulli Irelli; Enrico Michele Salamone; Biagio Orlando; Martina Fanella; Emanuele Tinelli; Gabriele Ruffolo; Luigi Zuliani; Jinane Fattouch; Mario Manfredi; Anna Teresa Giallonardo; Carlo Di Bonaventura
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

Review 10.  Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging.

Authors:  Erwin A van Vliet; Nicola Marchi
Journal:  Epilepsia       Date:  2022-04-21       Impact factor: 6.740

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.